Trevi Therapeutics (TRVI) Tops Q1 EPS by 4c

Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• D-Wave Quantum (QBTS) call put ratio 5.3 calls to 1 put with a focus on July 26 and 30 calls as share price up 6.9%